Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CV9202 maintenance vaccination versus placebo after concurrent chemoradiation in inoperable stage III NSCLC
2014-004959-30Phase 2Terminated
- Sponsor
- Boehringer Ingelheim
- Start
- Sep 2015
- Modality
- mRNA Vaccines → Recombinant Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in non-small cell lung cancer (NSCLC) comparing BI 1361849 maintenance vaccination with Placebo sham-vaccine (2 arms). Primary endpoint: Progression-free survival. Started Sep 2015; status: terminated.
02
Drugs
CV9202
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2014-004959-30.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-004959-30.